EZH2 and cancer: Notably, it has been observed that in various cancers, including Rhabdomyosarcoma, there is over-expression of the catalytic subunit of the PRC2 complex, enhancer of zeste homolog 2 (EZH2), and its expression is linked to advanced disease stages and poor prognosis [47].